

IN THE CLAIMS:


Please replace all prior versions or listing of claims with the following:

1. (previously presented) A pharmaceutical aqueous suspension comprising:
 - a) a therapeutically effective amount of suspended solid particles in crystal form comprising at least one active ingredient;
 - b) a thickener;
 - c) a uniformly dispersed nucleation inhibitor; and
 - d) at least one amino polycarboxylic acid compound; andwherein the suspension has a pH of about 3.7 to 8.
2. (original) A suspension according to claim 1, wherein the suspended solid particles are hydrophobic and the suspension further comprises a surfactant.
3. (original) A suspension according to claim 1, wherein the suspended solid particles have a median particle size, as measured by laser scattering, of about 1 to about 20 microns.
4. (original) A suspension according to claim 1, wherein the suspension comprises a blend of at least a structuring agent and a swelling agent as the thickener.
5. (original) A suspension according to claim 1, wherein the active ingredient is substantially insoluble in an aqueous environment at room temperature.
6. (original) A suspension according to claim 1 wherein the aqueous suspension has a pH between 3 and 6 at room temperature.
7. (original) A suspension according to claim 1 wherein the nucleation inhibitor is polyvinylpyrrolidone.
8. (original) A suspension according to claim 1 wherein the pH of the aqueous suspension remains within 0.2 pH units for a period of at least four weeks starting from its complete formulation when stored at a temperature of at least 60°C.

9. (original) A suspension according to claim 1 wherein the viscosity remains constant for at least two weeks when stored at a temperature of at least 60°C.

10. (original) A suspension according to claim 1 wherein the viscosity within a range of plus or minus 25% of its initial value for a period of at least 8 weeks when stored at a temperature of 60°C.

11. (original) A suspension according to claim 1 wherein the amino polycarboxylic acid compound is a compound according to formula (I) and pharmaceutically acceptable salts thereof:




wherein R_1 and R_2 , independently of one another, are hydrogen, hydroxy-terminated C_1 - C_4 alkylene, carboxylic-terminated C_1 - C_4 alkylene or $N-[R_3OOH]_m$;

and R_3 , R_4 , R_5 and R_6 are independently of one another are C_1 - C_4 alkylene

and m is 1 or 2;

or formula (II)



wherein R_7 , R_8 and R_9 , independently of one another, are hydrogen, C_1 - C_4 alkyl, carboxylic-terminated C_1 - C_4 alkylene or hydroxy-terminated C_1 - C_4 alkylene

and pharmaceutically acceptable salts of formula (I) or (II).

12. (original) A suspension according to claim 11, wherein at least one amino polycarboxylic acid compound is represented by formula (I) and R_1 , R_2 and R_3 are ethylene.

13. (original) A suspension according to claim 1, wherein the amino polycarboxylic acid compound is selected from the group consisting of ethylenediaminetetraacetic acid (EDTA), hydroxyethylethylenediaminetriacetic acid, dihydroxyethylethylenediaminediacetic acid, 1,3-propanediaminetetraacetic acid, diethylenetriaminepentaacetic acid, triethylenetetraminehexaacetic acid, iminodiacetic acid, methyliminodiacetic acid, nitrilotriacetic acid, and salts thereof, and mixtures thereof.

14. (original) A suspension according to claim 1, wherein the amino polycarboxylic acid compound is selected from ethylenediaminetetraacetic acid and salts thereof and mixtures thereof.
15. (original) A suspension according to claim 1, wherein the amino polycarboxylic acid compound is disodium ethylenediaminetetraacetate.
16. (original) A suspension according to claim 11 wherein the active ingredient is an anti-histamine or analgesic.
17. (original) A suspension according to claim 14 wherein the active ingredient is loratadine.
18. (original) A suspension according to claim 16 wherein the active ingredient is acetaminophen or ibuprofen.
19. (previously presented) A pharmaceutical aqueous suspension comprising:
- a) a therapeutically effective amount of suspended solid particles in crystal form comprising at least one active ingredient;
 - b) a blended thickening component comprising xanthan gum and pre-gelatinized starch;
 - c) at least one amino polycarboxylic acid compound; and
- wherein the suspension has a pH of about 3.7 to 8.
20. Cancel
21. (original) A suspension according to claim 19 further comprising a surfactant.
22. (previously presented) A pharmaceutical aqueous suspension comprising a therapeutically effective amount of suspended solid particles in crystal form comprising at least one active ingredient selected from the group consisting of fexofenadine, loratadine, desloratadine, terfenadine, astemizole, norastemizole, cetirizine, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof, wherein the suspension has a pH of about 3.7 to 8; and

wherein the suspended solid particles have a median particle size, as measured by laser scattering, of about 1 to about 20 microns after 4 weeks at 60°C.